94 related articles for article (PubMed ID: 27943563)
1. Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study).
Sulkowski MS; Flamm S; Kayali Z; Lawitz EJ; Kwo P; McPhee F; Torbeyns A; Hughes EA; Swenson ES; Yin PD; Linaberry M
Liver Int; 2017 Jun; 37(6):836-842. PubMed ID: 27943563
[TBL] [Abstract][Full Text] [Related]
2. Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study.
Shin SK; Lee JW; Ra H; Kwon OS; Shin JB; Jin YJ; Lee S; Han KJ; Kim YN; Kim TH; Kim YS; Kim JH
J Korean Med Sci; 2019 Oct; 34(41):e264. PubMed ID: 31650719
[TBL] [Abstract][Full Text] [Related]
3. Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy.
Uchida Y; Naiki K; Kouyama JI; Sugawara K; Nakao M; Motoya D; Inao M; Nakayama N; Imai Y; Tomiya T; Mochida S
PLoS One; 2018; 13(10):e0205600. PubMed ID: 30308053
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of generic sofosbuvir in the treatment of chronic hepatitis C virus infection in Saudi patients.
AlGhamdi HS; AlHabobi AA; AlQahtani RS; Ghomraoui FA; AlThiab KM; AlOun AA; AlAlwan AM; Abdelmahmoud MB; AlTraif IH; Aljumah AA
Saudi Med J; 2023 Dec; 44(12):1240-1247. PubMed ID: 38016752
[TBL] [Abstract][Full Text] [Related]
5. Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network.
Kondili LA; Gaeta GB; Brunetto MR; Di Leo A; Iannone A; Santantonio TA; Giammario A; Raimondo G; Filomia R; Coppola C; Amoruso DC; Blanc P; Del Pin B; Chemello L; Cavalletto L; Morisco F; Donnarumma L; Rumi MG; Gasbarrini A; Siciliano M; Massari M; Corsini R; Coco B; Madonia S; Cannizzaro M; Zignego AL; Monti M; Russo FP; Zanetto A; Persico M; Masarone M; Villa E; Bernabucci V; Taliani G; Biliotti E; Chessa L; Pasetto MC; Andreone P; Margotti M; Brancaccio G; Ieluzzi D; Borgia G; Zappulo E; Calvaruso V; Petta S; Falzano L; Quaranta MG; Weimer LE; Rosato S; Vella S; Giannini EG
PLoS One; 2017; 12(10):e0185728. PubMed ID: 28977040
[TBL] [Abstract][Full Text] [Related]
6. Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antivirals.
Liu CH; Chang YP; Lee JY; Chen CY; Kao WY; Lin CL; Yang SS; Shih YL; Peng CY; Lee FJ; Tsai MC; Huang SC; Su TH; Tseng TC; Liu CJ; Chen PJ; Kao JH
J Med Virol; 2024 May; 96(5):e29675. PubMed ID: 38746997
[TBL] [Abstract][Full Text] [Related]
7. Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature.
Haga Y; Kanda T; Yasui S; Nakamura M; Ooka Y; Takahashi K; Wu S; Nakamoto S; Arai M; Chiba T; Maruyama H; Yokosuka O; Takada N; Moriyama M; Imazeki F; Kato N
Oncotarget; 2018 Jan; 9(4):5509-5513. PubMed ID: 29435197
[TBL] [Abstract][Full Text] [Related]
8. A case report of sofosbuvir and daclatasvirto treat a patient with acute hepatitis C virus genotype 2 monoinfection.
Li C; Hu J
Medicine (Baltimore); 2018 Apr; 97(15):e0416. PubMed ID: 29642211
[TBL] [Abstract][Full Text] [Related]
9. A Review of Daclatasvir Drug-Drug Interactions.
Garimella T; You X; Wang R; Huang SP; Kandoussi H; Bifano M; Bertz R; Eley T
Adv Ther; 2016 Nov; 33(11):1867-1884. PubMed ID: 27664109
[TBL] [Abstract][Full Text] [Related]
10. Successful Anti-HCV Therapy of a Former Intravenous Drug User with Sofosbuvir and Daclatasvir in a Peritranspant Setting: A Case Report.
Seifert LL; Heinzow H; Kabar I; Christensen S; Hüsing A; Schmidt HH
Am J Case Rep; 2016 Aug; 17():605-10. PubMed ID: 27554644
[TBL] [Abstract][Full Text] [Related]
11. High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study.
Flower B; McCabe L; Le Ngoc C; Le Manh H; Le Thanh P; Dang Trong T; Vo Thi T; Vu Thi Kim H; Nguyen Tat T; Phan Thi Hong D; Nguyen Thi Chau A; Dinh Thi T; Tran Thi Tuyet N; Tarning J; Kingsley C; Kestelyn E; Pett SL; Thwaites G; Nguyen Van VC; Smith D; Barnes E; Ansari MA; Turner H; Rahman M; Walker AS; Day J; Cooke GS
Open Forum Infect Dis; 2021 Jul; 8(7):ofab267. PubMed ID: 34337093
[TBL] [Abstract][Full Text] [Related]
12. Optimization of direct anti-viral agent treatment schedule: Focus on HCV genotype 3.
Morisco F; Granata R; Camera S; Ippolito A; Milella M; Conti F; Masetti C; Smedile A; Tundo P; Santantonio T; Valvano MR; Termite A; Gatti P; Messina V; Iacobellis A; Librandi M; Caporaso N; Andriulli A;
United European Gastroenterol J; 2018 Mar; 6(2):225-237. PubMed ID: 29511552
[TBL] [Abstract][Full Text] [Related]
13. Serum MicroRNA profiles in chronic hepatitis C Egyptian patients before and after combined sofosbuvir and daclatasvir treatment.
Ezzat WM; Amr KS; Tawfeek S; Elbatae H; Bayomi EA; Heiba A; Elhosary Y
BMC Infect Dis; 2024 Jan; 24(1):67. PubMed ID: 38195397
[TBL] [Abstract][Full Text] [Related]
14. Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis.
Sperl J; Frankova S; Kreidlova M; Merta D; Tothova M; Spicak J
Ther Clin Risk Manag; 2017; 13():733-738. PubMed ID: 28790832
[TBL] [Abstract][Full Text] [Related]
15. Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure.
Abo-Amer YE; Badawi R; El-Abgeegy M; Elsergany HF; Mohamed AA; Mostafa SM; Alegaily HS; Soliman S; Elnawasany S; Abd-Elsalam S
Adv Virol; 2020; 2020():9075905. PubMed ID: 32774374
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C Retreatment With First-Line Direct Acting Antiviral Drugs.
Goel A; Katiyar H; Mayank ; Tiwari P; Rungta S; Verma A; Deep A; Sana A; Rai P; Aggarwal R
J Clin Exp Hepatol; 2023; 13(5):736-741. PubMed ID: 37693269
[TBL] [Abstract][Full Text] [Related]
17. Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era.
Hariri S; Sharafi H; Sheikh M; Merat S; Hashemi F; Azimian F; Tamadoni B; Ramazani R; Gouya MM; Abbasi B; Tashakorian M; Alasvand R; Alavian SM; Poustchi H; Malekzadeh R
Harm Reduct J; 2020 Oct; 17(1):80. PubMed ID: 33081794
[TBL] [Abstract][Full Text] [Related]
18. HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients.
Morgan JR; Savinkina A; Pires Dos Santos AG; Xue Z; Shilton S; Linas B
Adv Ther; 2021 Mar; 38(3):1690-1700. PubMed ID: 33590445
[TBL] [Abstract][Full Text] [Related]
19. The Efficacy and Safety of Sofosbuvir and Daclatasvir Treatment in Children and Adolescents With Thalassemia and Hepatitis C Virus Infection.
Samadder RK; Ray G; Dutta S; Hazra A; Sadhukhan P; Chowdhury A; Ray R; Ahammed SM
J Clin Exp Hepatol; 2024; 14(3):101310. PubMed ID: 38264577
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
